2019 Payment Schedule Test Updates

The table below reflects Records of Decision associated with laboratory tests under the Laboratory Services Act in BC.

LSA ROD #

Approvals Granted

LSA2019-008

Amendment to the Preamble to the Laboratory Services Outpatient Payment Schedule.

Effective April 1, 2019, the Preamble to the Laboratory Services Outpatient Payment Schedule is amended to reflect updates regarding the following subjects:

  1. The Payment Schedule Index of Amendments is removed to reflect the current Record of Decision (ROD) process.
  2. The definition of prescribed agency was revised for greater clarity with distinction from a “program” or a “branch”.
  3. The definition of healthcare practitioners was updated according to the current regulations and enrollment practice.
The addition of language regarding Laboratory Services Agreements to explicitly address payments under terms of an Agreement.
LSA2019-005

Amended Cervical Cancer Screening Laboratory Requisition 00050902 v2 (January 2019)

Effective February 28, 2019 the Ministry of Health has approved an amended Cervical Cancer Screening Laboratory Requisition. Implementation and utilization of the Cervical Cancer Screening Laboratory Requisition 00050902 v2 (January 2019) is required by August 31, 2019.

LSA2019-003

Effective March 15, 2019, the Laboratory Services Fee For Service Outpatient Laboratory Facility Approval Categories (PDF, 248KB) will be amended as follows:

Addition of the following 1 fee item in Facility Approval Category 2A:

  • 90170 FIBRIN/FIBRINOGEN DEGRADATION/INCLUDING D - DIMER

Addition of the following 3 fee items in Facility Approval Category 2C:

  • 91930 LIPASE
  • 92045 PH, PC02 AND P02
  • 91896 LACTATE – WHOLE BLOOD
LSA2019-002

Effective May 1, 2019, the Laboratory Services Outpatient Payment Schedule will be amended as follows:

The provisional status of fee item 92277 Thiopurine Metabolite (TM) is extended for 12 months, to April 30, 2020.

LSA2019-002

Effective March 1, 2019, the Laboratory Services Outpatient Payment Schedule will be amended as follows:

Modify the title of fee item 91460 from Dehydroepiandrosterone, serum (DHEA) to Dehydroepiandrosterone, serum (DHEA-S).